For example, the results of the clinical trial of bexarotene (RXR agonist) suggests that it may reduce brain amyloid and increases serum Aβ1–42 in ApoE4 noncarriers in mild to moderate AD patients [94]. This evidence concerns the gene APOE and Alzheimer disease.